When a patient presents with a red, hot, swollen and painful joint, reliably differentiating infection from inflammation poses a significant global problem.
Typical wait times for culture results vary from 24hrs to 21 days, with a true positivity of up to 20%, meaning they are inconclusive more than 80% of the time.
Rather than risk missing or misdiagnosing an infection, the current approach sees the patient admitted to hospital and treated with antibiotics.
This results in uncertainty for patients and clinicians, increased costs to the hospital, and poorer outcomes.
With up to 95% negative and positive predictive value and results in ~3 hours, Synvichor provides rapid and reliable differentiation of joint pain.
Synvichor helps to rapidly assess which patients require urgent treatment for infection, and which patients can be safely managed in the community for non-infectious inflammation.
1. Graue C et al. Open Forum Infect Dis. 2020; 7(Suppl 1):S233–4.
Synvichor has been designed to fit into your existing testing and work-up routine for all patients with undifferentiated joint pain.
Synvichor sets a new global medical standard that enhances surgeon’s treatment decisions, improves outcomes for patients, and reduces the burden on the hospital system.See how
Synvichor has the potential to deliver savings of up to $2.5B annually to the Australian healthcare system and increase hospital capacity by over 100,000 bed days per year